Brean Murray Carret & Co. Starts NuVasive (NUVA) at Buy, Expectations Conservative
Tweet
Share
E-mailGet Alerts NUVA Hot Sheet
Price: $39.75 --0%
Rating Summary:
11 Buy, 21 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Rating Summary:
11 Buy, 21 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 9
Join SI Premium – FREE
Brean Murray Carret & Co. initiates coverage on NuVasive (NASDAQ: NUVA) with a Buy. PT $30.00.
The firm comments, "We think expectations are conservative, now that the company has successfully defended its core US Lumbar business, and with upside opportunities from the pipeline — Attrax ™ in Biologics, Japanese expansion, and a
new cervical disc (likely in 2013)."
For an analyst ratings summary and ratings history on NuVasive click here. For more ratings news on NuVasive click here.
Shares of NuVasive closed at $22.16 yesterday.
The firm comments, "We think expectations are conservative, now that the company has successfully defended its core US Lumbar business, and with upside opportunities from the pipeline — Attrax ™ in Biologics, Japanese expansion, and a
new cervical disc (likely in 2013)."
For an analyst ratings summary and ratings history on NuVasive click here. For more ratings news on NuVasive click here.
Shares of NuVasive closed at $22.16 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Victoria's Secret (VSCO) initiated with sell rating at Goldman Sachs on 'less attractive' risk/reward
- Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
- Wells Fargo Starts Americold Realty Trust (COLD) at Equal Weight
Create E-mail Alert Related Categories
New CoverageRelated Entities
Brean Murray Carret & Co.Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
